Summit Therapeutics Files 8-K
Ticker: SMMT · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
TL;DR
Summit Therapeutics filed a routine 8-K, no major news yet.
AI Summary
On March 12, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate reporting by Summit Therapeutics Inc. to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- March 12, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36866 (commission_file_number) — SEC File Number
- 37-1979717 (irs_number) — IRS Employer Identification No.
- 601 Brickell Key Drive, Suite 1000, Miami, FL 33131 (address) — Principal Executive Offices
- (650) 460-8308 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD disclosures and to report financial statements and exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Summit Therapeutics Inc.
In which state was Summit Therapeutics Inc. incorporated?
Summit Therapeutics Inc. was incorporated in Delaware.
What is the SEC file number for Summit Therapeutics Inc.?
The SEC file number for Summit Therapeutics Inc. is 001-36866.
What is the address of the principal executive offices?
The address of the principal executive offices is 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-03-12 08:36:10
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
Filing Documents
- smmt-20240312.htm (8-K) — 29KB
- barclayshealthcareconfer.htm (EX-99.1) — 29KB
- barclayshealthcareconfer001.jpg (GRAPHIC) — 90KB
- barclayshealthcareconfer002.jpg (GRAPHIC) — 253KB
- barclayshealthcareconfer003.jpg (GRAPHIC) — 117KB
- barclayshealthcareconfer004.jpg (GRAPHIC) — 114KB
- barclayshealthcareconfer005.jpg (GRAPHIC) — 102KB
- barclayshealthcareconfer006.jpg (GRAPHIC) — 75KB
- barclayshealthcareconfer007.jpg (GRAPHIC) — 107KB
- barclayshealthcareconfer008.jpg (GRAPHIC) — 119KB
- barclayshealthcareconfer009.jpg (GRAPHIC) — 158KB
- barclayshealthcareconfer010.jpg (GRAPHIC) — 119KB
- barclayshealthcareconfer011.jpg (GRAPHIC) — 135KB
- barclayshealthcareconfer012.jpg (GRAPHIC) — 117KB
- barclayshealthcareconfer013.jpg (GRAPHIC) — 128KB
- barclayshealthcareconfer014.jpg (GRAPHIC) — 108KB
- barclayshealthcareconfer015.jpg (GRAPHIC) — 133KB
- barclayshealthcareconfer016.jpg (GRAPHIC) — 211KB
- barclayshealthcareconfer017.jpg (GRAPHIC) — 103KB
- barclayshealthcareconfer018.jpg (GRAPHIC) — 95KB
- barclayshealthcareconfer019.jpg (GRAPHIC) — 92KB
- barclayshealthcareconfer020.jpg (GRAPHIC) — 88KB
- barclayshealthcareconfer021.jpg (GRAPHIC) — 80KB
- 0001599298-24-000040.txt ( ) — 3722KB
- smmt-20240312.xsd (EX-101.SCH) — 2KB
- smmt-20240312_def.xml (EX-101.DEF) — 14KB
- smmt-20240312_lab.xml (EX-101.LAB) — 25KB
- smmt-20240312_pre.xml (EX-101.PRE) — 15KB
- smmt-20240312_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 12, 2024, Summit Therapeutics, Inc. (the "Company") presented at Barclays' 26th Annual Global Healthcare Conference, which was held in Miami Beach, FL. A copy of the presentation is attached as Exhibit 99.1 to this current Report on Form 8-K and is incorporated by reference herein. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Presentation Slides made available on March 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: March 12, 2024 By: /s/ Ankur Dhingra Chief Financial Officer (Principal Financial Officer)